HC Wainwright Has Bullish Estimate for IPA FY2025 Earnings

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Equities research analysts at HC Wainwright boosted their FY2025 earnings estimates for ImmunoPrecise Antibodies in a research note issued to investors on Monday, March 31st. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.17) per share for the year, up from their prior forecast of ($0.27). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q4 2025 earnings at ($0.02) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.08) EPS and FY2027 earnings at $0.01 EPS.

Separately, Benchmark restated a “speculative buy” rating and set a $3.00 target price on shares of ImmunoPrecise Antibodies in a research report on Tuesday.

ImmunoPrecise Antibodies Trading Up 5.2 %

Shares of IPA stock opened at $0.38 on Thursday. The business’s fifty day moving average price is $0.43 and its 200 day moving average price is $0.47. The firm has a market capitalization of $11.78 million, a PE ratio of -0.49 and a beta of 0.09. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.85. ImmunoPrecise Antibodies has a 1-year low of $0.27 and a 1-year high of $1.50.

ImmunoPrecise Antibodies (NASDAQ:IPA) last released its earnings results on Friday, March 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $4.23 million for the quarter, compared to analysts’ expectations of $6.59 million. ImmunoPrecise Antibodies had a negative return on equity of 73.74% and a negative net margin of 114.50%.

Institutional Investors Weigh In On ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC increased its position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,558,892 shares of the company’s stock after purchasing an additional 263,451 shares during the quarter. Ingalls & Snyder LLC owned 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent filing with the SEC. Institutional investors own 6.70% of the company’s stock.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.